Expert Matthew Lunning, DO, FACP, reviews the case of a 73-year-old woman with R/R DLBCL, considering current and emerging treatment strategies in this setting.
EP. 1: Patient Case: A 73-Year-Old Woman with Relapsed/Refractory DLBCL
EP. 2: A Review of 3L+ Treatments for DLBCL
A comprehensive overview of third-line relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and bispecific antibodies.
EP. 3: LOTIS-2 Trial: Loncastuximab Tesirine for R/R DLBCL
Dr. Lunning, an expert in lymphoma, discusses the results and clinical significance of the LOTIS-2 trial, evaluating loncastuximab tesirine for patients with R/R DLBCL.
EP. 4: Evaluating the L-MIND and RE-MIND2 Trials in the Real-World Setting
Matthew Lunning, DO, FACP, evaluates the clinical trial data from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on real-world outcomes.
EP. 5: Clinical Perspectives in Later Line Therapies for R/R DLBCL
Expert shares clinical perspectives and treatment considerations regarding use of later lines of therapy for patients with R/R diffuse large B-cell lymphoma.
EP. 6: R/R DLBCL: Sequencing Strategies for Treating Disease Progression
A deep dive into treatment sequencing strategies in R/R DLBCL, sharing insights from clinical data and recently approved novel therapies.
EP. 7: Future Outlooks in an Evolving Landscape for R/R DLBCL
Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.
2 Commerce Drive Cranbury, NJ 08512